Department of Medical Services and Techniques, Hamidiye Vocational School of Health Services, University of Health Sciences, Üsküdar, 34668, İstanbul, Türkiye
Auto-generated profile, based on publicly available information
Ayşe Merve Şenol
Department of Medical Services and Techniques, Hamidiye Vocational School of Health Services, University of Health Sciences, Üsküdar, 34668, İstanbul, Türkiye
6-Hydroxychromone-derived hydrazones were synthesized and evaluated for their in vitro hCA I–II and AChE inhibitory activities, along with antioxidant properties.
19 January 2023 in Research on Chemical Intermediates
Lung cancer remains a leading cause of cancer-related deaths, largely due to therapy resistance and toxicity. This study develops novel quinazolinone-thiazolidinedione (TZD) hybrids by combining two anticancer pharmacophores to achieve more selective and potent EGFR inhibitors. A total of 14 quinazolinone-TZD hybrids were synthesized and characterized. Their cytotoxicity was evaluated in A549 lung adenocarcinoma and BEAS-2B normal bronchial cells. EGFR binding was analyzed via molecular docking and MM-GBSA, with 500 ns molecular dynamics simulations supporting the stability of selected complexes. ADME predictions assessed drug-likeness and oral bioavailability. Several compounds showed selective cytotoxicity against A549 cells, with compound 9 (thiophen-2-ylmethyl substituent) emerging as the most active (IC50 = 3.85 μM, SI = 36.0), outperforming gefitinib (IC50 = 9.59 μM, SI = 1.9) and exhibiting higher selectivity than sorafenib (IC50 = 3.24 μM, SI = 5.4). Computational analyses revealed key interactions with EGFR residues (Cys-797, Arg-841, Asn-842, and Phe-997), supported by stable molecular dynamics behavior and favorable ADME predictions. These findings indicate that the synthesized hybrids, particularly compound 9, represent promising leads for selective EGFR-targeted lung cancer therapy and support further optimization.
1 October 2021 in Colloids and Surfaces B: Biointerfaces